Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study

Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study

This study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). Patient are randomized to two groups: atorvastatin pre-treatment group (80mg atorvastatin two days before PCI) and control group (PCI without atorvastatin pretreatment). Endpoint is myocardial infarction measured by troponin I and creatine kinase myocardial band.

Randomized studies have shown that pre-treatment with atorvastatin may reduced periprocedural myocardial in patient with stable angina during elective PCI. These data provide evidence-based support for using atorvastatin 7 days before PCI (dosage 40mg/d), alternatively three or more days (unknown dosage). We want to confirm this results for shorter pre-treatment period (two days) with dosage 80mg per day.

Inclusion Criteria:

• stable angina in last month
• indication for percutaneous coronary intervention
• informed consent

Exclusion Criteria:

• acute coronary syndrome in last 14 days
• renal insufficiency (creatinine more 150 µmol/l)
• diseases severely limiting prognosis
• immunosuppressive treatment
• statin one month before randomization
• occlusion of the coronary artery
• previous participation in this study